Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD

2.58  -0.02 (-0.77%)

Fundamental Rating

3

Taking everything into account, THTX scores 3 out of 10 in our fundamental rating. THTX was compared to 560 industry peers in the Biotechnology industry. While THTX is still in line with the averages on profitability rating, there are concerns on its financial health. THTX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year THTX has reported negative net income.
THTX had a negative operating cash flow in the past year.
THTX had negative earnings in each of the past 5 years.
THTX had negative operating cash flow in 4 of the past 5 years.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

THTX has a better Return On Assets (-6.57%) than 86.79% of its industry peers.
THTX's Return On Invested Capital of 45.67% is amongst the best of the industry. THTX outperforms 99.82% of its industry peers.
Industry RankSector Rank
ROA -6.57%
ROE N/A
ROIC 45.67%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

THTX's Operating Margin of 13.89% is amongst the best of the industry. THTX outperforms 94.11% of its industry peers.
With an excellent Gross Margin value of 78.97%, THTX belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
In the last couple of years the Gross Margin of THTX has grown nicely.
Industry RankSector Rank
OM 13.89%
PM (TTM) N/A
GM 78.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), THTX is creating value.
THTX has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for THTX has been reduced compared to 5 years ago.
The debt/assets ratio for THTX is higher compared to a year ago.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.10, we must say that THTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.10, THTX is not doing good in the industry: 66.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.1
ROIC/WACC3.98
WACC11.48%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

THTX has a Current Ratio of 1.08. This is a normal value and indicates that THTX is financially healthy and should not expect problems in meeting its short term obligations.
THTX has a worse Current ratio (1.08) than 87.68% of its industry peers.
A Quick Ratio of 0.88 indicates that THTX may have some problems paying its short term obligations.
The Quick ratio of THTX (0.88) is worse than 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 0.88
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.89% over the past year.
Looking at the last year, THTX shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
Measured over the past years, THTX shows a small growth in Revenue. The Revenue has been growing by 6.31% on average per year.
EPS 1Y (TTM)86.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%17.23%

3.2 Future

THTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.71% yearly.
The Revenue is expected to grow by 6.62% on average over the next years.
EPS Next Y147.68%
EPS Next 2Y84.18%
EPS Next 3Y56.99%
EPS Next 5Y29.71%
Revenue Next Year-1.97%
Revenue Next 2Y6.24%
Revenue Next 3Y6.74%
Revenue Next 5Y6.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

THTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 10.29, the valuation of THTX can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of THTX indicates a rather cheap valuation: THTX is cheaper than 96.25% of the companies listed in the same industry.
THTX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.20.
Industry RankSector Rank
PE N/A
Fwd PE 10.29
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

96.25% of the companies in the same industry are more expensive than THTX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

THTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
THTX's earnings are expected to grow with 56.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y84.18%
EPS Next 3Y56.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

NASDAQ:THTX (5/28/2025, 2:57:19 PM)

2.58

-0.02 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-09 2025-04-09/bmo
Earnings (Next)07-08 2025-07-08/bmo
Inst Owners25.27%
Inst Owner Change-8.13%
Ins Owners0.91%
Ins Owner ChangeN/A
Market Cap118.63M
Analysts84
Price Target4.05 (56.98%)
Short Float %1.23%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-255.34%
Min EPS beat(2)-410.68%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-50.01%
Min EPS beat(4)-410.68%
Max EPS beat(4)216.48%
EPS beat(8)5
Avg EPS beat(8)-9.56%
EPS beat(12)6
Avg EPS beat(12)-18.07%
EPS beat(16)7
Avg EPS beat(16)-18.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)6.97%
Revenue beat(4)1
Avg Revenue beat(4)-3.14%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-7.88%
Revenue beat(12)1
Avg Revenue beat(12)-6.64%
Revenue beat(16)1
Avg Revenue beat(16)-8.6%
PT rev (1m)-0.96%
PT rev (3m)-3.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-157.14%
EPS NY rev (1m)0%
EPS NY rev (3m)13.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.29
P/S 1.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 11
EPS(TTM)-0.08
EYN/A
EPS(NY)0.25
Fwd EY9.71%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.93
BVpS-0.53
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.57%
ROE N/A
ROCE 57.81%
ROIC 45.67%
ROICexc 57.36%
ROICexgc N/A
OM 13.89%
PM (TTM) N/A
GM 78.97%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score3
Asset Turnover1.57
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.04
Cap/Depr 424.28%
Cap/Sales 13.09%
Interest Coverage 1.49
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 0.88
Altman-Z -7.1
F-Score3
WACC11.48%
ROIC/WACC3.98
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y147.68%
EPS Next 2Y84.18%
EPS Next 3Y56.99%
EPS Next 5Y29.71%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%17.23%
Revenue Next Year-1.97%
Revenue Next 2Y6.24%
Revenue Next 3Y6.74%
Revenue Next 5Y6.62%
EBIT growth 1Y264.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y34.67%
FCF growth 1Y-14.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.38%
OCF growth 3YN/A
OCF growth 5YN/A